Long-term follow-up study of patients with adrenal incidentalomas.
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The incidence of adrenal incidentalomas has sharply increased in recent decades and concurrent subtle endocrine abnormalities, or even subclinical conditions, have been identified. Nonetheless, data concerning possible changes in adrenal size and/or hormonal pattern during follow-up are still inadequate. OBJECTIVE: To evaluate long-term morphological and functional evolution of adrenal incidentalomas after initial diagnosis and to identify possible risk factors for hormonal hyperactivity and mass enlargement. PATIENTS: Sixty-four patients (34-79 years) were followed-up for 12-120 months (median 25.5 months). Initial computerized tomography scan showed a unilateral mass in 51 patients and bilateral lesions in 13 patients. Average mass diameter at diagnosis was 2.5+/-0.1 cm (range 1.0-4.0). Twelve patients had subclinical Cushing's syndrome, 41 had mild hormonal alterations, and 11 had normal adrenal function at baseline. All patients were investigated by morphological and functional evaluation 6 and 12 months after diagnosis, and then at 1-year intervals. RESULTS: During follow-up, a mass size increase >/=1 cm was observed in 13 patients, and 18 developed further subtle endocrine alterations. Cumulative risk of developing endocrine abnormalities was 17% at 1 year, 29% at 2 years, and 47% at 5 years. The risk was higher in the first 2 years of follow-up if the initial tumor diameter was >or=3 cm. Overall, cumulative risk of mass enlargement was 6% at 1 year, 14% at 2 years, and 29% at 5 years, and it was greater in patients with normal adrenal function than in those with subtle hormonal abnormalities (P<0.05). One female subject showed a mass enlargement after 6 months of follow-up and was eventually diagnosed with non-Hodgkin's lymphoma. CONCLUSIONS: Patients with an adrenal incidentaloma are at risk for tumor growth and development of hormonal alterations. The risk of adrenal malignancy, although not elevated, also indicates the need for long-term follow-up.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bulow et al. (31) reported 2% prevalence of Cushing's syndrome; Libe et al. (32) reported 18%; Terzolo et al. (21) quoted 5-20%, depending on referral bias and diagnostic tests and criteria.”
From The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. (2008) · cites this paper as [32]
In the citing paper
“However, if the lowest cutoffs were used [1.8 and 2.2 g/dl (50 and 60.6 nmol/liter), respectively], specificity decreased to 67-72%, whereas sensitivity increased to 75-100% (48 -62, 64 -67).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
In the citing paper
“Overall, in these studies, the different parameters showed a good specificity (90 -98%, using 1-mg DST) but, generally, a poor sensitivity (41-86% using ACTH levels).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
In the citing paper
“two studies suggested that in patients with an adrenal mass more than 2 cm in size, the estimated cumulative risk of developing SH may vary between 7 and 47% after 5 yr (50,52).”
From Diagnosis and Treatment of Subclinical Hypercortisolism (2011) · cites this paper as [52]
Citations
Cites
A Survey on Adrenal Incidentaloma in Italy
Mantero, F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.2.637 · Cited by 855
Incidentally Discovered Adrenal Masses*
KLOOS, R. T., GROSS, M. D., FRANCIS, I. R., KOROBKIN, M., & SHAPIRO, B. (1995) · Endocrine Reviews · doi:10.1210/edrv-16-4-460 · Cited by 828
MANAGEMENT APPROACHES TO ADRENAL INCIDENTALOMAS
Young, W. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70122-5 · Cited by 415
Reincke, M. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.75.3.826 · Cited by 348 · cited 1×
“As previously reported (6, 9, 10 ), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low o…”
BackgroundInfluentialSubclinical Cushing’s syndrome
Reincke, M. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70115-8 · Cited by 285
Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1
Barzon, L., Scaroni, C., Sonino, N., Fallo, F., Paoletta, A., & Boscaro, M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.2.5444 · Cited by 254 · cited 1×
“Recently, Barzon et al. (14) evaluated long-term clinical, hormonal, and morphological outcomes in patients with adrenal incidentalomas in order to obtain prognostic factors for disease progression. European Journal of Endocrinology (2002) 147 489–494 ISSN 0804-4643”
BackgroundSerendipitous adrenal masses: Prevalence, significance, and management
Abecassls, M., McLoughlin, M. J., Langer, B., & Kudlow, J. E. (1985) · The American Journal of Surgery · doi:10.1016/s0002-9610(85)80186-0 · Cited by 233
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas)
Osella, G., Terzolo, M., Borretta, G., Magro, G., Alí, A., Piovesan, A., Paccotti, P., & Angeli, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.6.7989452 · Cited by 206
Subclinical Cushing's syndrome in adrenal incidentaloma.
Terzolo, Osella, Alì, Borretta, Cesario, Paccotti, & Angeli, A. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00357.x · Cited by 198 · cited 1×
“However, in our retrospective study no patient showed an evolution to overt clinical hypercortisolism, in agreement with previous reports ( 11 , 15).”
ResultAbnormalities of endocrine function in patients with clinically silent adrenal masses.
Ambrosi, B., Peverelli, S., Passini, E., Re, T., Ferrario, R., Colombo, P., Sartorio, A., & Faglia, G. (1995) · European Journal of Endocrinology · doi:10.1530/eje.0.1320422 · Cited by 136 · cited 2×
“As previously reported ( 6 , 9, 10), SCS was defined by the absence of signs or symptoms of hypercortisolism and by the presence of at least two of the following criteria: inadequate cortisol inhibition after 1 mg dexamethasone (cortisol levels $ 138 nmol/l), high or high – normal UFC excretion ($ 275 nmol/24 h), low…”
BackgroundMethodInfluentialSelf-citation
Cited by
Items 101–200 of 216
Wang, T. S., Cheung, K., Roman, S. A., & Sosa, J. A. (2012) · Surgery · doi:10.1016/j.surg.2012.08.011 · Cited by 18
Terzolo, M., Reimondo, G., & Angeli, A. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0473 · Cited by 20
Two-year follow-up of thirty-two non-functional benign adrenal incidentalomas
Yılmaz, H., Tütüncü, N. B., & Şahin, M. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345772 · Cited by 18
Differentiation of Adrenal Adenomas From Metastases With Unenhanced Computed Tomography
Gufler, H., Eichner, G., Großmann, A., Krentz, H., Schulze, C. G., Sauer, S., & Grau, G. (2004) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-200411000-00015 · Cited by 17
Federal clinical practice guidelines on the diagnostics and treatment of adrenocortical cancer
Mel'nichenko, G. A., Stilidi, I. S., Alekseev, B. Y., Gorbunova, V. A., Beltsevich, D. G., Райхман, А. О., Kuznetsov, N. S., Zhukov, N. V., & Bokhyan, V. Y. (2014) · Problems of Endocrinology · doi:10.14341/probl201460251-67 · Cited by 19
“Достаточно часто среди инциденталом выявляется феномен субклинического гиперкортицизма (8—12% наблюдений) [10].”
Will, O., Hansmann, A., Phillips, R. K. S., Palazzo, F. F., Meeran, K. M., Marshall, M., & Clark, S. K. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3181a876d6 · Cited by 16
Adrenal tumors: An experience of 10 years in a single surgical unit
Khanna, S., Priya, R., Bhartiya, S., Basu, S., & Shukla, V. K. (2015) · Indian Journal of Cancer · doi:10.4103/0019-509x.176749 · Cited by 16
Adipokine and cytokine levels in non-functioning adrenal incidentalomas (NFAI)
Babińska, A., Kaszubowski, M. F., & Sworczak, K. (2018) · Endocrine Journal · doi:10.1507/endocrj.ej18-0066 · Cited by 16
“pl Adrenal incidentalomas considered hormonally inactive in the past have often been found to exhibit subclinical hormonal activity of the cortex or medulla [6-10].”
BackgroundAdrenal Incidentaloma Controversial Size Recommendations
Jackson, B. S. (2023) · Urology Research and Practice · doi:10.5152/tud.2023.22245 · Cited by 20
Castro, M. A., Ramírez, P. A. P., Lázaro, C. R., García-Centeno, R., Gimeno, P. G., Fernández-Ladreda, M. T., Núñez, M. A. S., Marazuela, M., Escobar-Morreale, H. F., & Valderrábano, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235509 · Cited by 15
“Other studies identified tumour size [17,18], bilaterality and low/suppressed ACTH values [17] to be predictive factors of ACS development in NFAIs.”
BackgroundWhen to Intervene for Subclinical Cushing's Syndrome
Hsieh, L. B., MacKinney, E. C., & Wang, T. S. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.04.011 · Cited by 17
Markers of Subclinical Cardiovascular Disease in Patients with Adrenal Incidentaloma
Szychlińska, M., Baranowska-Jurkun, A., Matuszewski, W., Wołos-Kłosowicz, K., & Bandurska-Stankiewicz, E. M. (2020) · Medicina · doi:10.3390/medicina56020069 · Cited by 18
Maehana, T., Tanaka, T., Itoh, N., Masumori, N., & Tsukamoto, T. (2012) · Indian Journal of Urology · doi:10.4103/0970-1591.98461 · Cited by 13
“Libe et al.[11] reported that only 40% of SCS patients had a low ACTH level, with a cutoff level of 0.7 pmol/L (3.18 pg/ml).”
BackgroundInfluentialJaniak, K., Jóźwik−Plebanek, K., & Kamiński, G. (2024) · Endokrynologia Polska · doi:10.5603/ep.100278 · Cited by 15
Akkuş, G., Evran, M., Sert, M., Ok, F., & Tetıker, T. (2017) · Health Science Reports · doi:10.1002/hsr2.22 · Cited by 15
Large Adrenal Incidentalomas Require a Dedicated Diagnostic Procedure
Amodru, V., Taïeb, D., Guérin, C., Paladino, N. C., Brue, T. Y., Sebag, F. A., & Castinetti, F. (2019) · Endocrine Practice · doi:10.4158/ep-2018-0616 · Cited by 13
Síndrome de Cushing: situaciones especiales
Iriarte, M. J. G. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)71408-1 · Cited by 15
Giorgi, R. B., Correa, M. V., Costa‐Barbosa, F. A., & Kater, C. E. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2018-00385 · Cited by 14
Adrenal mass in patients who underwent abdominal computed tomography examination
El-Menyar, A. A., Al-Sulaiti, M., Elgohary, H., Almalki, A., Asim, M., Tabeb, A., & Al-Thani, H. A. S. (2015) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.157482 · Cited by 16
“[15] However, some investigators suggested a correlation between tumor size (>3 cm) at diagnosis, hormonal hyperfunction, and tumor growth.[31,37] Bernini et al.”
BackgroundCorwin, M. T., Chalfant, J. S., Loehfelm, T. W., Fananapazir, G., Lamba, R., & Mayo-Smith, W. W. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.17.18543 · Cited by 11
Approach to the Patient with an Incidental Adrenal Mass
He, X., Peter, P. R., & Auchus, R. J. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.009 · Cited by 15
Draft of the clinical practice guidelines “Adrenal incidentaloma”
Beltsevich, D. G., Troshina, E. A., Mel'nichenko, G. A., Platonova, N. M., Ladygina, D. O., & Chevais, A. (2021) · Endocrine Surgery · doi:10.14341/serg12712 · Cited by 12
Incidentalomas suprarrenales: experiencia clínica en los hospitales de Castilla-La Mancha
Lamas, C., Palma, M., Martín, D., de Frutos, V. Á., López, M., & Marco, A. (2009) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(09)72708-1 · Cited by 8
Adrenal masses (diagnosis and differential diagnosis)
Молашенко, Н. В., Юкина, М. Ю., Soldatova, T. V., & Рогаль, Е. А. (2010) · Problems of Endocrinology · doi:10.14341/probl201056148-56 · Cited by 10
Adrenal incidentalomas and subclinical Cushing’s syndrome
Abdelmannan, D. K., & Aron, D. C. (2010) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-010-9141-5 · Cited by 8
Ecografía de bazo y retroperitoneo
Joven, I. S., Segura-Grau, A., Rodríguez, N. D., & Segura-Cabral, J. M. (2015) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2015.02.007 · Cited by 8
Intsidentaloma nadpochechnikov
Beltsevich, D. G., Kuznetsov, N. S., Soldatova, T. V., & Vanushko, V. E. (2009) · Endocrine Surgery · doi:10.14341/2306-3513-2009-1-19-23 · Cited by 8
Vélayoudom, F.-L., Cardot-Bauters, C., Decouvelaere, A., Vlaeminck‐Guillem, V., Bauters, F., & Wemeau, J. L. (2005) · Annales d Endocrinologie · doi:10.1016/s0003-4266(05)82113-4 · Cited by 8
“The prevalence of adrenal incidentaloma fluctuates between 1 and 5% [19, 21].”
BackgroundCollienne, M., Timmesfeld, N., Bergmann, S. R., Goebel, J. N., & Kann, P. H. (2015) · Ultraschall in der Medizin - European Journal of Ultrasound · doi:10.1055/s-0041-107996 · Cited by 8
“additionally proclaimed stagnation after two years [11].”
BackgroundUpdate on the Diagnosis of Cushing Syndrome
Liu, H., & Crapo, L. M. (2005) · The Endocrinologist · doi:10.1097/01.ten.0000162374.56442.ea · Cited by 9
Tabarin, A., Bardet, S., Bertherat, J. Y., Chabre, O., Dupas, B., Hamoir, E., Laurent, F., Tenenbaum, F., Cazalda, M., Rohmer, V., et al. (2008) · Annales d Endocrinologie · doi:10.1016/j.ando.2008.09.002 · Cited by 9
“[115] Libe R, Dall’Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P, Ambrosi”
Starker, L. F., Prieto, P. A., Liles, J. S., Cao, H. S. T., Grubbs, E. G., Lee, J. E., Perrier, N. D., & Graham, P. H. (2016) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2016.04.001 · Cited by 8
Change in the pattern of adrenal venous sampling over time in patients with primary aldosteronism
Murashima, M., Trerotola, S. O., Fraker, D. L., Han, D., Townsend, R. R., & Cohen, D. L. (2008) · Journal of Human Hypertension · doi:10.1038/jhh.2008.108 · Cited by 8
Enberg, U., Hennings, J., Volpe, C., Hellman, P., Höög, A., Hamberger, B., & Thoren, M. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345750 · Cited by 8
How to approach and follow adrenal incidentaloma?
Oh, J. Y. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.5.541 · Cited by 7
“The cumulative risk of mass enlargement was 6% at 1 year, 14% at 2 years, and 29% at 5 years, and it was greater in patients with normal adrenal function than in those with subtle hormonal abnormalities [1].”
BackgroundSaini, J., Salama, B., Yu, K., Chacko, S. R., Han, A. J., Villavicencio, C. A., Murad, M. H., & Bancos, I. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf136 · Cited by 7
Automated extraction of incidental adrenal nodules from electronic health records
Schumm, M. A., Hu, M.-Y. Y., Sant, V. R., Kim, J., Tseng, C., Sanz, J., Raman, S. S., Yu, R., & Livhits, M. J. (2022) · Surgery · doi:10.1016/j.surg.2022.07.028 · Cited by 7
Risk of concomitant malignancy in hyperfunctioning adrenal incidentalomas
Allan, B. J., Thorson, C. M., Haren, R. M. V., Parikh, P. P., & Lew, J. I. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.03.032 · Cited by 6
Prise en charge d’un hypercorticisme
Rosales, C., Fierrard, H., BERTAGNA, X. Y., & Raffin‐Sanson, M. (2008) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2007.11.007 · Cited by 8
Parazzoli, C., Favero, V., Aresta, C., & Morelli, V. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1179817 · Cited by 6
“confirmed that the cumulative risk of developing an ACS increases with time and is higher after 5 years (15, 25).”
BackgroundInfluentialLee, J.-M., Kim, M. K., Ko, S., Koh, J., Kim, B., Kim, S.-W., Kim, S., Kim, H. J., Ryu, O., Park, J., et al. (2017) · Korean Journal of Medicine · doi:10.3904/kjm.2017.92.1.4 · Cited by 5
Hormonal Evaluation of Incidental Adrenal Masses: The Exception, Not the Rule
Kirsch, M. J., Hsu, K., Lee, M. H., Pickhardt, P. J., Kim, D. H., Sippel, R. S., & Dedhia, P. H. (2020) · World Journal of Surgery · doi:10.1007/s00268-020-05679-9 · Cited by 5
Giudice, F. D., Kim, W., Li, S., BERARDINIS, E. D., Sciarra, A., Salciccia, S., Ferro, M., Riccardo Autorino, B., Pandolfo, S. D., Crocetto, F., et al. (2022) · Minerva Urology and Nephrology · doi:10.23736/s2724-6051.22.05073-x · Cited by 5
Guidelines for the management of the incidentally discovered adrenal mass
Kapoor, A., Morris, T., & Rebello, R. (2013) · Canadian Urological Association Journal · doi:10.5489/cuaj.657 · Cited by 6
Screening Tests for Hypercortisolism in Patients With Adrenal Incidentaloma
Ferreira, L., Oliveira, J. C., & Palma, I. (2018) · Journal of Endocrinology and Metabolism · doi:10.14740/jem510w · Cited by 5
Li, L., Yang, G., Dou, J., Gu, W., Lv, Z., Lu, J., & Mu, Y. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-101236 · Cited by 4
“In recent years, more incidentalomas have been detected by imaging, which are increasingly likely to be functional because of the more detailed evaluations for subclinical syndromes [10, 14].”
BackgroundDoes IGF-1 play a role in the etiopathogenesis of non-functioning adrenocortical adenoma?
Bahadır, Ç. T., Ecemiş, G. C., & Atmaca, H. N. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0869-1 · Cited by 5
Tasaki, M., Kasahara, T., Takizawa, I., Saito, K., Nishiyama, T., & Tomita, Y. (2019) · International braz j urol · doi:10.1590/s1677-5538.ibju.2018.0235 · Cited by 5
“The main concern in the hormonal follow-up of benign nonfunctioning adrenal tumors is the development of autonomous cortisol secretion without signs of overt Cushing’s syndrome (subclinical Cushing’ syndrome) (10, 22).”
BackgroundDifferential diagnostics of adrenal incedentaloma
Kuznetsov, N. S., Beltsevich, D. G., Vanushko, V. E., Soldatova, T. V., Ремизов, О. В., Kats, L. E., & Lysenko, M. A. (2011) · Endocrine Surgery · doi:10.14341/2306-3513-2011-1-5-16 · Cited by 6
Trastornos de la glándula suprarrenal: diagnóstico y tratamiento
Verónica, Q. A. (2013) · Revista Médica Clínica Las Condes · doi:10.1016/s0716-8640(13)70222-0 · Cited by 7
“3- Seguimiento De acuerdo a las diferentes series, hasta 20% de los incidentalomas pueden aumentar de tamaño y hasta 25% puede llegar a transformarse en funcionante en un seguimiento a 5 años (32, 42).”
Laparoscopic transperitoneal adrenalectomy: Our initial results
ÖZGÖR, F. N., Binbay, M., Akbulut, M. F., Şimşek, A., Şahan, M., Berberoğlu, A. Y., Sarılar, Ö., & Müslümanoğlu, A. Y. (2014) · Urology Research and Practice · doi:10.5152/tud.2014.09076 · Cited by 4
“On the other hand, Liebe et al.[13] followed up 64 patients for 3 years, and reported development of endocrinological disorders in 28% of these patients, and higher risk in patients with adrenal masses greater than 3 cm in diameter.”
BackgroundA clinical audit: diagnostic and epidemiological evaluation of the adrenal incidentaloma
Nuzzo, V., Attardo, T. M., Augello, G., Brancato, D., Canale, C., Camerlingo, S., Coretti, F., Franco, A., Giacometti, F., Gambacorta, M., et al. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02780-3 · Cited by 3
Presentation and outcome of patients with an adrenal mass: A retrospective observational study
Nabi, T., Rafiq, N., Dar, S., & Rasool, S. (2020) · Clinical Cancer Investigation Journal · doi:10.4103/ccij.ccij_70_20 · Cited by 3
“[23] In a study by Giordano R, et al., 118 patients of adrenal masses with initial tumors size of 2.22 cm, an increase in the tumor size occurred in seven patients and a decrease in size was noted in two patients, when followed up for 3 years.”
BackgroundInfluentialFalcetta, P., Orsolini, F., Molinaro, E., Vitti, P., & Tonacchera, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00051 · Cited by 3
“(3), with only a few cases reported to date (4–8).”
BackgroundAkkuş, G., Aksoydan, Ü. P., Odabaş, F., Binokay, H., Sert, M., & Tetıker, T. (2025) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/0115734056347340241009102228 · Cited by 2
Bilateral Adrenal Lymphoma with Addison’s Disease: A Surgical Pitfall
Donckier, J. E., Lacrosse, M., & Michel, L. A. (2007) · Acta chirurgica Belgica · doi:10.1080/00015458.2007.11680045 · Cited by 2
Hormonal evaluation of adrenal incidentalomas
Loupp, A.-G. L., Cariou, B., Drui, D., Graveline, N., Masson, D., & Bach‐Ngohou, K. (2014) · Annales de biologie clinique · doi:10.1684/abc.2014.1013 · Cited by 2
Egan, R. J., & Scott-Coombes, D. M. (2018) · Springer eBooks · doi:10.1007/978-981-10-1124-5_25 · Cited by 2
Can non-functional adrenal incidentaloma be ranked among cardiovascular risk factors?
Yağız, B., Akalın, A., Yorulmaz, G., Macunluoğlu, A. C., & YAĞIZ, O. (2022) · The European Research Journal · doi:10.18621/eurj.872835 · Cited by 2
Non-medicalization of medical science: Rationalization for future
Mittal, M., Jethwani, P., Naik, D., & Garg, M. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i5.402 · Cited by 3
Conduite à tenir face à un incidentalome surrénalien associé à une hypertension artérielle
Mathonnet, M. (2005) · Annales de Chirurgie · doi:10.1016/j.anchir.2005.03.003 · Cited by 4
Draft of Russian Guidelines of Diagnosis and Treatment of Adrenal Cortical Cancer
Mel'nichenko, G. A., Stilidi, I. S., Горбунова, В. А., Alexeev, B. Y., Beltsevich, D. G., Райхман, А. О., Kuznetsov, N. S., Zhukov, N. V., & Bokhyan, V. Y. (2014) · Endocrine Surgery · doi:10.14341/serg201414-26 · Cited by 2
“Достаточно часто выявляется феномен субклинического гиперкортицизма – 8–12% наблюдений среди инциденталом [10, 11].”
Dreval, A. V., Владимировна, К. И., Murzina, A. V., Nechaeva, O., Степановна, Т. Р., Borodina, E., & Anashkina, G. A. (2014) · Problems of Endocrinology · doi:10.14341/probl20146019-17 · Cited by 1
The Evaluation and Follow-up of Adrenal Incidentaloma
Kim, S. G., & Choi, D. S. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.4.257 · Cited by 1
“외국의 보고들을 보면 기능성 종양 으로의 변화는 3~4년이 지나면 거의 발생하지 않았다[8,9].”
Large Asymptomatic Adrenal Incidentaloma
(2006) · The Internet Journal of Surgery · doi:10.5580/192d · Cited by 1
Di, D. G., Vicennati, V., Rinaldi, E., Morselli‐Labate, A. M., Giampalma, E., Mosconi, C., Pagotto, U., & Pasquali, R. (2012) · 15th International & 14th European Congress of Endocrinology · Cited by 1
Allolio, B., Nies, C., Moll, R., Klose, K., Kann, P. H., Pfestroff, A., Waldmann, J., Bartsch, D. K., Lehnert, H., Dralle, H., et al. (2012) · Springer eBooks · doi:10.1007/978-3-642-14285-7_4 · Cited by 1
Approach to the patient with adrenal incidentaloma. Case series
Ladygina, D. O., Zorina, A. A., Berkovskaya, M. A., Chevais, A., Beltsevich, D. G., & Fadeev, V. V. (2023) · Consilium Medicum · doi:10.26442/20751753.2023.4.202306 · Cited by 1
Advances in our understanding of the prognosis of adrenal incidentaloma
Mackay, I., & Aspinall, S. R. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2016.1233055 · Cited by 1
“documented higher risks of mass enlargement of 6, 14, and 29% at 1, 2, and 5 years, respectively [69].”
BackgroundLirov, R., & Gauger, P. G. (2018) · Springer eBooks · doi:10.1007/978-981-10-1124-5_26 · Cited by 1
Measurement of midnight ACTH levels is useful for the evaluation of midnight cortisol levels
Baba, R., Oki, K., Kobuke, K., Itcho, K., Okubo, H., Ohno, H., Yoneda, M., & Hattori, N. (2018) · Steroids · doi:10.1016/j.steroids.2018.10.011 · Cited by 1
Intraosseous Myelolipoma of Maxilla and Mandible
Jaewon, C., Paeng, J., & Ahn, J. (2019) · 대한구강악안면병리학회지 · doi:10.17779/kaomp.2019.43.5.012 · Cited by 1
Covey, A. M., & Brody, L. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-34062-5.00022-4 · Cited by 1
Síndrome de Cushing subclínico
Salvador, J., gÓmez, F., & Santos, E. (2004) · Endocrinología y Nutrición · doi:10.1016/s1575-0922(04)74618-5 · Cited by 1
La laparoscopie est-elle licite pour les grosses tumeurs de la surrénale ?
Cougard, P., & Sebag, F. A. (2004) · Annales de Chirurgie · doi:10.1016/j.anchir.2004.11.005 · Cited by 1
“Dans une étude [5], le devenir de 74 incidentalomes surrénaliens réévalués tous les ans pendant 1 à 12 ans a montré que le risque cumulé de développement d’une anomalie endocrinienne était de 17 % à un an, 19 % à deux ans et 47 % à cinq ans et le risque cumulé d’augmentation de la taille était de 6 % à un an, 14 % à d…”
TNF--a antagonists and sarcoidosis
Culver, D. A., & Baughman, R. P. (2011) · QJM · doi:10.1093/qjmed/hcr009 · Cited by 1
Pearls and Pitfalls of Imaging of the Adrenals
Kulawska-Didoszak, M., & Krestin, G. P. (2009) · Springer eBooks · doi:10.1007/978-3-540-85689-4_15
Adrenal Incidentalomas and Arterial Hypertension
Παππά, Θ., Kaltsas, G., Piaditis, G. P., & Chrousos, G. P. (2012) · Humana Press eBooks · doi:10.1007/978-1-60761-548-4_6
Adrenal incidentaloma's: are lessons still to be learned?
Das, G. C., Baglioni, P., Mallipedhi, A., & Okosieme, O. E. (2010) · QJM · doi:10.1093/qjmed/hcq096
Protocolo diagnóstico del incidentaloma suprarrenal
Buesa, M. A. (2012) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(12)70404-3
Adrenal incidentalomas: a simple guide to a disease of modern technology
Ghosh, S., Jones, M., & Swaminathan, K. (2010) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2010.407
For information on reprint requests of more than 101 and commercial reprints contact
Barbour, L. A., Cobin, R. H., DeGroot, L. J., Glinoer, D., Mandel, S. J., & Edwards, H. A. (2008)
Behavior to be adopted to face adrenal incidentaloma
Tristá, S. E. T., Gámez, M. C., & Peña, R. T. (2014) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 1
Masa suprarrenal clínicamente inaparente
Araya, V. (2009) · Medwave · doi:10.5867/medwave.2009.08.4076
Living Kidney Donors With Adrenal Incidentalomas: Are They Appropriate Donors?
Arpalı, E., Aslan, A., Scalea, J. R., Karataş, C., Akıncı, S., Altınel, M., & Koçak, B. (2015) · Urology · doi:10.1016/j.urology.2015.10.004
Adrenal insidentaloması olan 80 hastamızın klinik özellikleri
Kutbay, N. Ö., Yürekli, B. Ş., Koroglu, E. P., Makay, Ö., Erdoğan, M., Çetinkalp, Ş., Özgen, G., & Saygılı, F. (2015) · Ege Tıp Dergisi · doi:10.19161/etd.344130 · Cited by 1
“Adrenal insidentalomalar, adrenal dışı hastalıklar araştırılırken tesadüfen saptanan ≥ 1 cm kitlelerdir (8).”
DYNAMICS OF THE SIZES OF TUMOURS IN LONG;TERM SUPERVISION OF PATIENTS WITH ADRENAL INCIDENTALOMAS
Михайловна, Б. Н., Константинович, К. Л., Привалов, Ю. А., Навтанович, Н. А., Варламова, С. В., & Шабанова, О. Г. (2010) · Сибирский медицинский журнал (Иркутск)
Ogo, A., Watanabe, A., Ide, C., Maruta, T., Sakai, Y., Hiramatsu, S., Uesugi, N., & Shigematsu, K. (2008) · Institutional Repositories DataBase (IRDB) · doi:10.15017/12487 · Cited by 1
Diagnosis of adrenocortical cancer
Mel'nichenko, G. A., Stilidi, I. S., Alekseev, B. Y., Beltsevich, D. G., Райхман, А. О., Kuznetsov, N. S., Zhukov, N. V., & Bokhyan, V. Y. (2014) · P A Herzen Journal of Oncology · doi:10.17116/oncolog2014690-94
Korrelation zwischen Nebennierenmorphologie und kardiovaskulären Parametern
Reincke, M., & Beuschlein, F. (2015)
"Diagnóstico e tratamento das massas adrenais clinicamente silenciosas: revisão de literatura"
Sette, M. J. A. (2005) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2005.tde-21122005-154758 · Cited by 1
Beltsevich, D. G., Russian Federation, & Russian, B. (2014) · Endocrine Surgery
Management Scheme for Adrenal Incidentalomas: Who Gets What?
Callender, G. G., & Udelsman, R. (2016) · Current Surgery Reports · doi:10.1007/s40137-016-0145-2
Диагностика адренокортикального рака
StiliDi, S., Kuznetsov, S. G., & Sechenov, M. (2014)
Stechman, M., & Scott-Coombes, D. M. (2019) · Wiley eBooks · doi:10.1002/9781118863343.ch16
Covey, A. M., & Brody, L. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1454-8.00020-5
Akın, Ş., Dağdelen, S., Yıldız, B. O., Gürlek, A., Erbas, T. A., & Bayraktar, M. (2020) · Kocatepe tıp dergisi. · doi:10.18229/kocatepetip.507301
Evaluation of Functionality and Growth Rates in Adrenal Incidentalomas: Single Center Experience
Avcı, S., OZTURKMEN, Y. A., Zuhur, S. S., Özkan, S. G., Güven, E., DEMİR, N., & Altuntaş, Y. (2020) · Phoenix Medical Journal · doi:10.38175/phnx.768414
“also found that non-functional and functional masses exhibited similar growth rates during their follow-ups (31).”
BackgroundNi, W., Chen, X., Ye, X., Pang, G., Liu, Y., & Yuan, X. (2021) · Research Square · doi:10.21203/rs.3.rs-144432/v1
Du, K., Heilbrun, M. E., & Bishoff, J. T. (2015) · Springer eBooks · doi:10.1007/978-3-319-23464-9_26
Metadata
- Authors
- Libe, R., Dall'Asta, C., Barbetta, L., Baccarelli, A., Beck-Peccoz, P., & Ambrosi, B.
- Affiliations
- University of Milan (IT)
- National Institutes of Health (US)
- Corresponding author
- Ambrosi, B
- ORCID
- Baccarelli, A
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10-01
- Volume
- 147
- Issue
- 4
- Pages
- 489-494
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2134170847
- Cited by
- 215
- References
- 21
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 6 · 2022: 5 · 2021: 7 · 2020: 13 · 2019: 14 · 2018: 7 · 2017: 11 · 2016: 10 · 2015: 11 · 2014: 13 · 2013: 5 · 2012: 14
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Keywords
- adrenal incidentaloma, subclinical Cushing's syndrome, adrenal hyperfunction, tumor growth, long-term follow-up, risk factors, adrenal function, adrenal malignancy, non-Hodgkin lymphoma
- MeSH terms
- Adrenal Gland Neoplasms, Adult, Aged, Cushing Syndrome, Dexamethasone, Female, Follow-Up Studies, Glucocorticoids, Humans, Hydrocortisone, Male, Middle Aged, Retrospective Studies, Risk Factors, Tomography, X-Ray Computed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.